Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse

  1. Michel Kalamarides1,
  2. Michiko Niwa-Kawakita1,
  3. Hélène Leblois2,
  4. Vincent Abramowski1,
  5. Michel Perricaudet2,
  6. Anne Janin3,
  7. Gilles Thomas1,
  8. David H. Gutmann4, and
  9. Marco Giovannini1,5
  1. 1INSERM U434, Fondation Jean Dausset–Centre d'Etude du Polymorphisme Humain, 75010 Paris, France; 2UMR1582 Institut Gustave Roussy, 94805 Villejuif, France; 3Laboratory of Pathology INSERM ERIT-M 0209, 75010 Paris, France; 4Department of Neurology, Washington University School of Medicine, St. Louis, Missouri 63110-1093, USA

Abstract

Biallelic NF2 gene inactivation is common in sporadic and in neurofibromatosis type 2 (NF2)-related meningiomas. We show that, beginning at four months of age, thirty percent of mice with arachnoidal cell Cre-mediated excision of Nf2 exon 2 developed a range of meningioma subtypes histologically similar to the human tumors. Additional hemizygosity for p53 did not modify meningioma frequency or progression suggesting that Nf2 andp53 mutations do not synergize in meningeal tumorigenesis. This first mouse model initiated with a genetic lesion found in human meningiomas provides a powerful tool for investigating tumor progression and for the preclinical evaluation of therapeutic interventions.

Keywords

Footnotes

  • 5 Corresponding author.

  • E-MAIL marco{at}cephb.fr; FAX 33-1-5372-5192.

  • Article and publication are at http://www.genesdev.org/cgi/doi/10.1101/gad.226302.

    • Received January 25, 2002.
    • Accepted March 27, 2002.
| Table of Contents

Life Science Alliance